Presentation
Is Survival Advantage Gained by the Addition of Bevacizumab to Chemotherapy for the Treatment of Recurrent, Persistent, or Advanced Cervical Cancer Worth the Additional Cost? A Cost-Effectiveness Analysis
Society of Gynecologic Oncology Annual Meeting on Women’s Cancer
(2014)
Disciplines
Publication Date
March, 2014
Location
Tampa, FL
Comments
Additional authors: Eric D. Schroeder, Ximena Burbano-Levy, Joseph de la Garza, Arlene E. Garcia-Soto, Karina E. Hew, Fausto Andrade, Fiona Simpkins, J. Mathew Pearson, Joseph A. Lucci
Citation Information
John Diaz. "Is Survival Advantage Gained by the Addition of Bevacizumab to Chemotherapy for the Treatment of Recurrent, Persistent, or Advanced Cervical Cancer Worth the Additional Cost? A Cost-Effectiveness Analysis" Society of Gynecologic Oncology Annual Meeting on Women’s Cancer (2014) Available at: http://works.bepress.com/john-diaz/43/